One person dies from brain cancer every 7 hours.
Glioblastoma (GBM) is the most diagnosed and deadliest of brain tumours in adults. And in the last 30 years, very limited new treatment options have been released.
But there is hope. Coming this November, a new way of fighting brain cancer will be available to Australian GBM patients ... GBM AGILE.
As the world's first global "adaptive" clinical trial for brain cancer, GBM AGILE allows glioblastoma patients to quickly share in the benefits of more effective therapies at a faster, more effective pace.
Providing new hope where little currently exists.
These trials can help up to 50 GBM patients per year to access new, potential beneficial therapies and it's coming to Australia.
From diagnosis to death, he only lasted three months.
– Tegan Irvine, her father Brad was diagnosed with stage 4 glioblastoma at 51.
A Revolution In Brain Cancer Treatment
We have a lot to accomplish. And we need your help.
Your impact will ...
Improve the overall survival in patients with newly diagnosed or recurrent GBM. Becoming a partner for one of the GBM AGILE trials will help secure the long-term future of these trials to Australian patients and will help ...
Implement a novel Australian scientific system compatible with the prevailing clinical trial framework.
Help GBM AGILE serve as a long-standing platform to test multiple therapies and treatments.
Create a more cost-effective medical research system within Australia and de-risk investment in brain cancer.
Create a learning system and gather patient data to inform further brain cancer research.
Give patients real hope and engender an advocacy movement in brain cancer.
Provide a platform for other diseases to replicate and inform.
We are at a tipping point in brain cancer;
the time is coming when patients will no longer be given their diagnosis and told there is no hope.
They will instead be told there are treatment options, that don't involve debilitating side effects. Funding an adaptive trial like GBM AGILE will help make this vision a reality.
– Professor Webster Cavenee (PhD)
Co-Founder and Board Member of GCAR
GBM AGILE
In the News
Cure Brain Cancer Foundation Invests in GBM AGILE
Cure Brain Cancer Foundation, the leading charity for brain cancer research, awareness and advocacy in the region, has announced a partnership with the Global Coalition for Adaptive Research to bring a revolutionary, first of its kind clinical trial …